The therapeutic potential of SGK3 inhibition has been particularly promising in oncology, where it overcomes drug resistance in HER2+ breast cancer and counteracts rapamycin resistance via mTORC1 reactivation (26, 47). Here, ERBB2 is linked to breast carcinoma.